Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.

Rupa GuhaBinbin YueJianping DongAditi BanerjeeGinette Serrero

Published in: Breast cancer research and treatment (2021)

PGRN/GP88 represents a therapeutic target with companion diagnostics. Blocking PGRN/GP88 with antibody treatment may provide novel-targeted solutions in TNBC treatment which could eventually address the issue of toxicity and unresponsiveness associated with SOC.

Keyphrases

oxidative stress
quantum dots
cancer therapy
highly efficient
drug delivery